Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer.
[BACKGROUND] This study evaluates the cost-effectiveness of tucatinib plus trastuzumab compared to pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or
APA
Liu M, Zhong L, et al. (2026). Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer.. Expert review of pharmacoeconomics & outcomes research, 1-11. https://doi.org/10.1080/14737167.2026.2642646
MLA
Liu M, et al.. "Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer.." Expert review of pharmacoeconomics & outcomes research, 2026, pp. 1-11.
PMID
41789524
Abstract
[BACKGROUND] This study evaluates the cost-effectiveness of tucatinib plus trastuzumab compared to pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (CRC) from the perspective of healthcare payers in China.
[RESEARCH DESIGN AND METHODS] An economic evaluation utilizing a 3-state partitioned survival model assessed the cost-effectiveness of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab.
[RESULTS] When the price of tucatinib was based on that of lapatinib in China, the estimated cost for tucatinib plus trastuzumab was higher than that of pertuzumab plus trastuzumab (29,130.32 USD vs 12,160.58 USD). The estimated utility was also greater compared to that of pertuzumab plus trastuzumab (2.07 QALYs vs 1.07 QALYs). The ICER was calculated at 17,075.25 USD/QALY, suggesting the tucatinib plus trastuzumab treatment was cost-effective compared to pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic CRC at a WTP threshold of 40,000 USD/ QALY.
[CONCLUSIONS] Tucatinib plus trastuzumab was cost-effective if its price was the same as lapatinib for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic CRC from the perspective of healthcare payers in China. Our exploratory result could provide a reference for clinical application of tucatinib plus trastuzumab when they are correctly interpreted.
[RESEARCH DESIGN AND METHODS] An economic evaluation utilizing a 3-state partitioned survival model assessed the cost-effectiveness of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab.
[RESULTS] When the price of tucatinib was based on that of lapatinib in China, the estimated cost for tucatinib plus trastuzumab was higher than that of pertuzumab plus trastuzumab (29,130.32 USD vs 12,160.58 USD). The estimated utility was also greater compared to that of pertuzumab plus trastuzumab (2.07 QALYs vs 1.07 QALYs). The ICER was calculated at 17,075.25 USD/QALY, suggesting the tucatinib plus trastuzumab treatment was cost-effective compared to pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic CRC at a WTP threshold of 40,000 USD/ QALY.
[CONCLUSIONS] Tucatinib plus trastuzumab was cost-effective if its price was the same as lapatinib for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic CRC from the perspective of healthcare payers in China. Our exploratory result could provide a reference for clinical application of tucatinib plus trastuzumab when they are correctly interpreted.
같은 제1저자의 인용 많은 논문 (5)
- CDH17 facilitates β-catenin nuclear translocation to reduce drug sensitivity in cisplatin-resistant gastric cancer cells.
- Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer.
- Metabolic engineering of SLC38A2 reprograms glutamine utilization and enhances CAR-macrophage antitumor function in solid tumors.
- Triangulating Associations Between Fruit Intake and Lung Cancer Risk: Evidence from GBD Estimates, Mendelian Randomization, and Real-World Validation.
- Cell-free supernatant of Clostridium butyricum induces mitochondrial apoptosis and suppresses NF-κB pathway in colorectal cancer cells.